| English |
|---|
| Title | 99mTechnetium Labeled Compounds |
|---|
| Subtitle | Proceedings of the 7th Annual Meeting of the Japanese Society of Nuclear Medicine XIII. Invited Lectures by the Foreign Lecturers |
|---|
| Authors | P. RICHARDS, H. L. ATKINS |
|---|
| Authors(kana) | |
|---|
| Organization | Nuclear Engineering Department, Medical Research Department Brookhaven National Laboratory Upton |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 5 |
|---|
| Number | 3 |
|---|
| Page | 165-170 |
|---|
| Year/Month | 1968/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] The radionuclide 99mTc has played an important role in the rapid growth of nuclear medciine due to its combination of excellent physical characteristics and its ready availability from the 99Mo-99mTc generator, The development of compounds labeled with 99mTc having different biological distributions has greatly increased its usefulness and made it the nuclide of choice for several applications. A detailed study of the chemistry invovled in labeling human serum albumin with technetium has resulted in the development of a reproducible method for labeling with high efficiency and the production of a product of high specific activity. As a result of these studies a new compound, 99mTc-DTPA, has been prepared which may further enhance the usefulness of the nuclide in nuclear medicine. The authors are indebted to Mr. James Baranosky for technical assistance in these studies. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|